A spinout company co-founded by Official Fellow Mark Coles has launched with $11 million seed financing to develop new therapies against inflammatory disease and cancer.
The news was captured by Business Weekly, a Cambridge-based news outlet focused on business, innovation and technology.
Read our news story
Business Weekly (26/04/2021)
